Clinical trials: Trifluridine and Tipiracil
Gastric Adenocarcinoma, Esophagus Adenocarcinoma
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic gastric, oesophageal or gastroesophageal junction cancer.
- Conditions
- Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- LOGICAN (NCT05476796)
- Testing
- Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen
- Where
- 28 sites in France
- Volunteers
- 118 people
- Sponsor
- UNICANCER
Metastatic Colorectal Cancer
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines…
- Trial name
- COLSTAR (NCT05223673)
- Testing
- Futuximab/modotuximab, Trifluridine/Tipiracil
- Where
- 15 sites in United States, Belgium and 4 more
- Volunteers
- 7 people
- Sponsor
- Institut de Recherches Internationales Servier
Colo-rectal Cancer, Third-line and Beyond Therapy
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine/tipiracil plus bevacizumab in refractory metastatic colorectal cancer.
- Conditions
- Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102, Bevacizumab
- Trial name
- NCT07085169
- Testing
- Trifluridine/tipiracil (TAS-102) plus bevacizumab
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Colorectal Cancer, Colorectal Carcinoma
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
This is a phase I clinical trial assessing the safety and recommended phase II dose of cabozantinib in combination with trifluridine/tipiracil (TAS102) in patients with metastatic colorectal carcinoma (mCRC).
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Metastatic Cancer, CRC
- Trial name
- NCT04868773
- Testing
- Cabozantinib, TAS-102
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Irvine
First-line Treatment, Advanced Colorectal Cancer
Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC
This is a two-group, parallel, randomized, standard-control phase II study comparing the safety and efficacy of trifluridine/tipiracil combined with oxaliplatin and bevacizumab versus XELOX plus bevacizumab in the first-line…
- Trial name
- TOBACO (NCT05077839)
- Testing
- Trifluridine/Tipiracil
- Where
- China
- Volunteers
- 184 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Colorectal Cancer
Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine
Unresectable metastatic colorectal cancer (mCRC) remains an incurable disease. After failure of conventional treatments involving fluoropyrimidines, oxaliplatin and irinotecan in combination or not with biotherapies targeting…
- Trial name
- TASKIN (NCT05201352)
- Testing
- trifluridine/tipiracil + XB2001
- Where
- 14 sites in France
- Volunteers
- 160 people
- Sponsor
- Centre Georges Francois Leclerc
Colorectal Neoplasms
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
This phase II trial studies how well stereotactic body radiotherapy (SBRT) followed by a combination of an immune checkpoint inhibitor (sintilimab), bevacizumab, and trifluridine/tipiracil (TAS-102) works as third-line treatment…
- Trial name
- BEST (NCT07535632)
- Testing
- SBRT, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Zhongshan Hospital
mCRC
Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
This single-center, single-arm, prospective study plans to enroll patients with advanced colorectal cancer who have failed first-line or higher systemic therapies.
- Trial name
- NCT07116577
- Testing
- Palliative radiotherapy, Iparomlimab and tuvonralimab, TAS-102
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Jinan Central Hospital
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Non-Small Cell Lung Cancer, Advanced Solid Tumors
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05029882
- Testing
- ABBV-400, Trifluridine/Tipiracil, Bevacizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Microsatellite-stable Colorectal Cancer, Standard of Care
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
To learn if the drug combination of BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab can help to control advanced or metastatic MSS-CRC.
- Conditions
- Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab
- Trial name
- NCT07011550
- Testing
- Nivolumab, Bevacizumab, BMS-986340
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Bioequivalence Study of Trifluridine and Tipiracil Tablets in Colorectal Cancer Patients
Trifluridine and Tipiracil Tablets is a nucleoside anti-metabolic and anti-cancer compound developed by Taiho (Dapeng) Co., Ltd., Japan, for the treatment of advanced colorectal cancer that inoperable resection, and progressed or…
- Trial name
- NCT03974594
- Testing
- Trifluridine and Tipiracil Tablets, TAS-102
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Refractory Metastatic Colorectal Cancer
Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer
This is a randomized, double-blind, placebo-controlled, multicenter study. The main purpose of the study is to evaluate the clinical efficacy and safety of nimotuzumab combined with trifluridine/tipiracil in third-line and beyond…
- Trial name
- NOTABLE-308 (NCT06343116)
- Testing
- Nimotuzumab injection, Trifluridine/tipiracil
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Metastatic Colorectal Cancer
A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)
A real-world study of trifluridine/tipiracil containing regimen for the treatment of patients with metastatic colorectal cancer. A total of 200 patients planned to be enrolled.
- Trial name
- NCT06195111
- Testing
- Trifluridine/Tipiracil
- Volunteers
- 200 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer
Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia
To compare the effects of TAS-102 with placebo in patients with metastatic colorectal cancer refractory or intolerable to standard chemotherapies.
- Trial name
- TERRA (NCT01955837)
- Testing
- TAS-102
- Where
- 4 sites in China, South Korea and 1 more
- Volunteers
- 406 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Refractory Metastatic Colorectal Cancer
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
This study is an investigator-initiated, prospective, multicenter, randomized, controlled, open-label, non-inferiority trial designed to evaluate the efficacy and safety of trifluridine/tipiracil plus fruquintinib versus…
- Trial name
- NCT07261709
- Testing
- Trifluridine/tipiracil plus fruquintinib, trifluridine/tipiracil plus bevacizumab
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Advanced Gastric Cancer
A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
To evaluate the efficacy and safety of trifluridine/tipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer
- Trial name
- NCT07371871
- Testing
- Trifluridine/Tipiracil (TAS-102) combined with Apatinib
- Volunteers
- 30 people
- Sponsor
- Anhui Provincial Cancer Hospital
Rectal Adenocarcinoma
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
A Prospective Single-Arm Study of Short-Course Radiotherapy Followed by PD-1 Monoclonal Antibody, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil for Total Neoadjuvant Therapy in MSS Locally Advanced Low Rectal Cancer.
- Trial name
- SCRIPBOT (NCT06872606)
- Testing
- Pucotenlimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Metastatic Colorectal Cancer, Drug Therapy
Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC
To evaluate the efficacy and safety of trifluridine/tipiracil combined with fufuquitinib versus trifluridine/tipiracil and fufuquitinib in patients with unresectable metastatic colorectal cancer.
- Trial name
- NCT06485713
- Testing
- trifluridine/tipiracil combined with fufuquitinib, fufuquitinib, Trifluridine/tipiracil
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Colorectal Cancer Metastatic
ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC
The objective of this randomized controlled clinical trial is to evaluate the efficacy of ctDNA-guided rechallenge with cetuximab plus trifluridine/tipiracil compared with bevacizumab plus trifluridine/tipiracil in patients with…
- Trial name
- NCT07012954
- Testing
- Cetuximab (Erbitux, C225), trifluridine/tipiracil, Bevacizumab ( Avastin)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-sen University